INDV enters its April 30 earnings release with momentum firmly behind it — but short sellers are quietly building positions even as the stock climbs.
The price action tells an optimistic story. INDV has gained 18% over the past month, closing at $34.31, with a further 5.8% added in the last week alone. Options traders are not pushing back against that move. The put/call ratio is running slightly below its 20-day average at 0.57, a full standard deviation lighter on defensive positioning than recent norms. Calls dominate, and with utilization at just 13% — well below the 52-week peak of 50.3% — the borrow market remains loose. Cost to borrow is negligible at 0.59%. None of this signals a crowded short trade.
Short interest, however, tells a different story. Bearish positioning has risen 37% over the past month, with shorts now holding 11% of the free float — nearly 13.8 million shares. That build began sharply around March 24, when short interest jumped from roughly 10.4 million shares to over 12.6 million in a single session, and has crept higher since. The ORTEX short score of 58.6 — in the moderate-elevated range — reflects that steady accumulation. Short sellers are not panicking into the print, but they are not retreating either.
The bull and bear camps have a clear disagreement about Sublocade's trajectory. Bulls point to strong patient volume growth — around 171,500 treated in Q3 2025, up 8% year-on-year — and an expanding prescriber base, with 11% more prescribers now writing the drug. Sales guidance of $825–$845 million frames the upside case. Bears focus on the sharp reduction in Sublocade's commercial footprint, now supported in only four countries versus roughly forty previously, alongside the discontinuation of Opvee. The bear case anticipates a ~6.5% revenue decline in 2026 as portfolio simplification actions take hold, even if EBITDA margins improve. With a consensus buy rating and a mean price target of $48.17, the Street leans bullish — but that 40% implied upside from current levels reflects real uncertainty about the pace of recovery. Valuation is not stretched on an earnings basis, with the stock trading at roughly 10.7x earnings and 7.8x EV/EBITDA, while the EPS surprise factor score at the 73rd percentile supports the idea that management has a track record of beating estimates. On the ownership side, BlackRock added over 9.5 million shares in Q1, taking its stake to nearly 15%, and Vanguard added 4 million shares — institutional conviction is building at the top of the register.
The April 30 print will test whether Sublocade's volume growth is enough to offset the revenue drag from the company's deliberate portfolio pruning, and whether management's EBITDA margin guidance can justify the sharp re-rating already baked into the past month's rally.
See the live data behind this article on ORTEX.
Open INDV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
